128 related articles for article (PubMed ID: 30443295)
1. Correction: Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor.
Hu Z; Hu Y; Liu X; Xi R; Zhang A; Liu D; Xie Q; Chen L
Oncotarget; 2018 Oct; 9(81):35283. PubMed ID: 30443295
[TBL] [Abstract][Full Text] [Related]
2. Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor.
Hu Z; Hu Y; Liu X; Xi R; Zhang A; Liu D; Xie Q; Chen L
Oncotarget; 2015 Oct; 6(31):31628-39. PubMed ID: 26375550
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation of mutationally introduced tyrosine in the activation loop of HER2 confers gain-of-function activity.
Hu Z; Wan X; Hao R; Zhang H; Li L; Li L; Xie Q; Wang P; Gao Y; Chen S; Wei M; Luan Z; Zhang A; Huang N; Chen L
PLoS One; 2015; 10(4):e0123623. PubMed ID: 25853726
[TBL] [Abstract][Full Text] [Related]
4. Correction: The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity
Shi F; Zhang J; Liu H; Wu L; Jiang H; Wu Q; Liu T; Lou M; Wu H
Oncotarget; 2018 Mar; 9(24):17255. PubMed ID: 29683149
[TBL] [Abstract][Full Text] [Related]
5. Correction: Targeting a ribonucleoprotein complex containing the caprin-1 protein and the c-Myc mRNA suppresses tumor growth in mice: an identification of a novel oncotarget.
Qiu YQ; Yang CW; Lee YZ; Yang RB; Lee CH; Hsu HY; Chang CC; Lee SJ
Oncotarget; 2019 Aug; 10(47):4919. PubMed ID: 31448057
[TBL] [Abstract][Full Text] [Related]
6. Correction: Genomic mutation-driven metastatic breast cancer therapy: a single center experience.
Yuan Y; Yost SE; Yim J; Yuan YC; Solomon NM; Mambetsariev I; Pal S; Frankel P; Salgia R; Neuhausen SL; Mortimer J
Oncotarget; 2017 Sep; 8(37):62817. PubMed ID: 28977992
[TBL] [Abstract][Full Text] [Related]
7. Correction: Inhibition of neddylation regulates dendritic cell functions
Cheng M; Hu S; Wang Z; Pei Y; Fan R; Liu X; Wang L; Zhou J; Zheng S; Zhang T; Lin Y; Zhang M; Tao R; Zhong J
Oncotarget; 2018 Dec; 9(99):37343. PubMed ID: 30647874
[TBL] [Abstract][Full Text] [Related]
8. Correction: Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia.
Sun H; Lin DC; Guo X; Masouleh BK; Gery S; Cao Q; Alkan S; Ikezoe T; Akiba C; Paquette R; Chien W; Müller-Tidow C; Jing Y; Agelopoulos K; Müschen M; Koeffler HP
Oncotarget; 2017 Sep; 8(38):64651. PubMed ID: 28969101
[TBL] [Abstract][Full Text] [Related]
9. Correction: Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides.
Tal P; Eizenberger S; Cohen E; Goldfinger N; Pietrokovski S; Oren M; Rotter V
Oncotarget; 2019 May; 10(34):3203-3206. PubMed ID: 31191814
[TBL] [Abstract][Full Text] [Related]
10. Correction:
Holien T; Misund K; Olsen OE; Baranowska KA; Buene G; Børset M; Waage A; Sundan A
Oncotarget; 2018 Nov; 9(89):36048. PubMed ID: 30542518
[TBL] [Abstract][Full Text] [Related]
11. Correction: Co-targeting translation and proteasome rapidly kills colon cancer cells with mutant
Li X; Li M; Ruan H; Qiu W; Xu X; Lin Z; Yu J
Oncotarget; 2018 Jan; 9(6):7271. PubMed ID: 29467964
[TBL] [Abstract][Full Text] [Related]
12. Correction: Checkpoint inhibitor induced cardiotoxicity: managing the drawbacks of our newest agents against cancer.
Brüstle K; Heidecker B
Oncotarget; 2018 Sep; 9(70):33440. PubMed ID: 30279972
[TBL] [Abstract][Full Text] [Related]
13. Correction: Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia.
Lee HJ; Lee J; Jeong P; Choi J; Baek J; Ahn SL; Moon Y; Heo JD; Choi YH; Chin YW; Kim YC; Han SY
Oncotarget; 2018 Apr; 9(28):20219. PubMed ID: 29733074
[TBL] [Abstract][Full Text] [Related]
14. Correction: A novel highly potent trivalent TGF-β receptor trap inhibits early-stage tumorigenesis and tumor cell invasion in murine Pten-deficient prostate glands.
Qin T; Barron L; Xia L; Huang H; Villarreal MM; Zwaagstra J; Collins C; Yang J; Zwieb C; Kodali R; Hinck CS; Kim SK; Reddick RL; Shu C; O'Connor-McCourt MD; Hinck AP; Sun LZ
Oncotarget; 2017 Aug; 8(34):57905. PubMed ID: 28915722
[TBL] [Abstract][Full Text] [Related]
15. Correction: PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix.
Mann M; Kumar S; Chauhan SS; Bhatla N; Kumar S; Bakhshi S; Gupta R; Sharma A; Kumar L
Oncotarget; 2019 Jul; 10(46):4802. PubMed ID: 31413820
[TBL] [Abstract][Full Text] [Related]
16. Correction: EGFR kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment.
Zhang H; Zhan C; Ke J; Xue Z; Zhang A; Xu K; Shen Z; Yu L; Chen L
Oncotarget; 2018 Oct; 9(81):35285. PubMed ID: 30443297
[TBL] [Abstract][Full Text] [Related]
17. Correction: Is alkaline phosphatase the smoking gun for highly refractory primitive leukemic cells?
Rico LG; Juncà J; Ward MD; Bradford J; Petriz J
Oncotarget; 2019 Mar; 10(23):2335. PubMed ID: 31040923
[TBL] [Abstract][Full Text] [Related]
18. Correction: A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma.
Zhu J; Wang M; Yu Y; Qi H; Han K; Tang J; Zhang Z; Zeng Y; Cao B; Qiao C; Zhang H; Hou T; Mao X
Oncotarget; 2019 Dec; 10(65):7010-7011. PubMed ID: 31857854
[TBL] [Abstract][Full Text] [Related]
19. Correction: Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor.
Chung S; Kijima K; Kudo A; Fujisawa Y; Harada Y; Taira A; Takamatsu N; Miyamoto T; Matsuo Y; Nakamura Y
Oncotarget; 2020 Oct; 11(41):3749-3750. PubMed ID: 33110482
[TBL] [Abstract][Full Text] [Related]
20. Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.
Robb CM; Kour S; Contreras JI; Agarwal E; Barger CJ; Rana S; Sonawane Y; Neilsen BK; Taylor M; Kizhake S; Thakare RN; Chowdhury S; Wang J; Black JD; Hollingsworth MA; Brattain MG; Natarajan A
Oncotarget; 2020 Jun; 11(25):2462-2463. PubMed ID: 32637035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
